CPHI South East Asia 2025
Panel Recap: Pharmacogenomics - Drugs That Kill?
Convention on Pharmacuetical Ingredients (CPHI)
Panel Discussion at the CPHI South East Asia 2025
- Prof. Dr. Teh Lay Kek, Faculty of Pharmacy, UiTM Puncak Alam
- Dr. Ngui Lock Hock, Head of Genetics, Hospital Kuala Lumpur
including the moderator, Mr. Ahmad Fazil bin Elias, Assistant Vice President of the Malaysian Bioeconomy Development Corporation. Our sincere thanks to Informa Markets and Bioeconomy Corporation for organizing this important platform to discuss on the revelation of personalized medicine for the future.
Reflections from the Session
Pharmacogenomics is steadily gaining ground as a valuable tool in optimising drug therapy and reducing adverse drug reactions. However, several key challenges remain:
- Limited practitioner exposure to genetic testing
- Gaps in access to actionable patient-level data
- Integration difficulties with clinical workflows and EMRs
During the session, PRECISE Pharmacogenomics was highlighted as Malaysia’s first clinically recommended genome-wide pharmacogenomics for drug-gene interactions. Developed based on internationally recognised guidelines, PRECISE is designed to support doctors in making more informed prescribing decisions across multiple therapeutic areas.
We remain committed to working alongside clinicians, researchers, and healthcare leaders to expand access to personalised diagnostics that are evidence-informed, clinically relevant, and suited for the needs of the Malaysian healthcare landscape.
